PuSH - Publikationsserver des Helmholtz Zentrums München: GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Abd-Ellah, A.* ; Voogdt, C.* ; Krappmann, D. ; Möller, P.* ; Marienfeld, R.B.*

GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.

Sci. Rep. 8:1352 (2018)

Verlagsversion

Forschungsdaten

DOI

PMC

	Open Access Gold

Abstract
Metriken
Zusatzinfos

Glycogen synthase kinase 3 beta (GSK3 beta) is a ubiquitously expressed serine/threonine kinase involved in the regulation of various cellular functions, such as energy homoeostasis, cell growth and developmental processes. More recently, GSK3 beta has been identified as a part of a protein complex involved in the regulation of the CARMA1-BCL10-MALT1 complex (CBM complex) formation, which is a key signalling event upon antigen receptor engagement of B and T cells, required for the activation of the NF-kappa B and JNK pathways. However, conflicting reports have been published regarding the role of GSK3 beta for the activation of the NF-kappa B signalling pathways. Therefore, we aimed to determine the impact of GSK3 beta on the NF-kappa B signalling induced upon T cell activation. Blocking GSK3 beta by either pharmacologic inhibitors (SB216763 and SB415286) or by RNAi caused a reduced proteolysis of the MALT1 targets CYLD1, BCL10 and RelB as well as diminished I kappa B alpha degradation, NF-kappa B DNA binding and NF-kappa B activity. This negative effect on NF-kappa B appears to be due to a diminished CBM complex formation caused by a reduced BCL10 phosphorylation. Taken together, we provide here evidence for a novel regulatory mechanism by which GSK3 beta affects NF-kappa B signalling in activated T cells.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

4.122

1.245